Allergy Therapeutics PLC
29 January 2008
TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES
(1). Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached:
Allergy Therapeutics PLC
2. Reason for the notification (please tick the appropriate box or boxes)
An acquisition or disposal of voting rights: ( X )
An acquisition or disposal of financial instruments which may result
in the acquisition of shares already issued to which voting rights are
attached: ( )
An event changing the breakdown of voting rights: ( )
Other (please specify) : ( )
3. Full name of person(s) subject to the notification obligation:
Fidelity International Limited (FIL)
4. Full name of shareholder(s) (if different from 3.):
See schedule below
5. Date of the transaction and date on which the threshold is crossed or reached
if different):
24 January 2008
6. Date on which issuer notified:
28 January 2008
7. Threshold(s) that is/are crossed or reached:
12%
8. Notified details:
A: Voting rights attached to shares
Class/type of shares Situation previous to
if possible using the the Triggering
ISIN CODE transaction
Number of shares Number of voting Rights
ISIN
GB00B02LCQ05 8,844,394 8,844,394
Resulting situation after the triggering transaction
Class/type of shares Number of shares Number of voting rights % of voting rights
if possible using
the ISIN CODE
Direct Direct Indirect Direct Indirect
ISIN
GB00B02LCQ05 10,624,594 12.96%
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Date Exercise/Conversion Number of voting % of voting
financial Period/ Date rights that may be rights
instrument acquired if the
instrument is
exercised/
converted.
Total (A+B)
Number of voting rights % of voting rights
10,624,594 12.96%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
See schedule below
Proxy Voting:
10. Name of the proxy holder:
Fidelity International Limited (FIL)
11. Number of voting rights proxy holder will cease to hold:
1,780,200
12. Date on which proxy holder will cease to hold voting rights:
24 January 2008
13. Additional information:
14. Contact name:
Fabio Correia
15. Contact:
fil-regulatoryreporting@uk.fid-intl.com
FIL
Issuer name: ALLERGY THERAPEUTICS PLC
Current ownership percentage: 12.96%
Total shares held: 10,624,594
Issued share capital: 81,950,632
SHARES HELD NOMINEE MANAGEMENT
COMPANY
Fidelity International Limited 145,000 BANK OF NEW YORK BRUSSELS FPM
(FIL) is the parent holding 237,533 BROWN BROS HARRIMN LTD LUX FIL
company for various direct and 831,000 JP MORGAN, BOURNEMOUTH FII
indirect subsidiaries, including 784,879 JP MORGAN, BOURNEMOUTH FIL
Fidelity Fund Management Limited 7,337,398 JP MORGAN, BOURNEMOUTH FISL
(FFML), Fidelity Investment 640,100 JP MORGAN, BOURNEMOUTH FPM
Services Limited (FISL), Fidelity 612,700 NORTHERN TRUST LONDON FPM
Gestion (FIGEST), Fidelity 35,984 STATE STR BK AND TR CO LNDN (S FPM
Investments Advisory (Korea) Limited
(FIAKL), Fidelity Investments
Management (Hong Kong) Limited (FIMHK),
Fidelity Pension Management (FPM),
Fidelity Investments Japan (FIJ) and
Fidelity Investments International
(FII), Investment managers for various
non-US investment companies and
institutional clients.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.